Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC)
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Investigating the efficacy of maintenance and reinduction treatment or no treatment and
watchful waiting in subjects with inoperable or irresectable and non-progressive metastatic
colorectal cancer after first line induction treatment for 24 weeks with a fluoropyrimidine-,
oxaliplatin- and bevacizumab-based chemotherapy.
The maintenance treatment with capecitabine or 5-FU/folinic acid and bevacizumab will be
compared with a maintenance treatment with bevacizumab alone or no maintenance treatment.
Reinduction treatment will be done in case of progression.
Phase:
Phase 3
Details
Lead Sponsor:
AIO-Studien-gGmbH
Collaborator:
Roche Pharma AG
Treatments:
Bevacizumab Capecitabine Fluorouracil Folic Acid Oxaliplatin Vitamin B Complex